🇺🇸 FDA
Pipeline program

BEAM-301: Single dose of BEAM-301 administered by IV

BTX-301-001

Phase 2 small_molecule active

Quick answer

BEAM-301: Single dose of BEAM-301 administered by IV for Glycogen Storage Disease Type Ia is a Phase 2 program (small_molecule) at Beam Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Beam Therapeutics
Indication
Glycogen Storage Disease Type Ia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials